Application of cantharidin, retinoic acid cream and salicylic acidy in multiple palmoplantar warts.
Skin Res Technol
; 30(2): e13586, 2024 Feb.
Article
en En
| MEDLINE
| ID: mdl-38279540
ABSTRACT
OBJECTIVE:
Multiple palmoplantar warts, caused by human papillomavirus (HPV) infection, were investigated for clinical efficacy using cantharidin, retinoic acid cream, and salicylic acid cream.METHODS:
A total of 110 patients with multiple palmoplantar warts were enrolled. The experimental group (54 cases) received a 111 combination (CRS) of 0.25% cantharidin, 0.1% retinoic acid cream, and 5% salicylic acid, applied with pressurized encapsulation for 8 h every night, three times per week. The control group (56 cases) underwent conventional liquid nitrogen freezing. Monthly follow-ups assessed cure rate, effective rate, dermatological life quality index (DLQI), visual analog scale (VAS), and cost, with evaluations conducted after 3 months.RESULTS:
The treatment group exhibited a cure rate of 85.19% and a total effective rate of 96.30%, surpassing the control group with rates of 39.29% and 51.79%, respectively (p < 0.05). The treatment group's DLQI score (1.84 ± 1.06) was significantly lower than the control group's score (6.04 ± 1.78) (p = 0.0005). Additionally, the treatment group's VAS score (1.84 ± 1.06) was notably lower than the control group's score (8.56 ± 1.07) (p < 0.0001). The treatment group's total cost (43.20 ± 2.85) was markedly lower than the control group's cost (206.38 ± 90.81), with a statistically significant difference (p < 0.0001).CONCLUSION:
The combination of cantharidin, retinoic acid cream, and salicylic acid with local encapsulation is a safe, effective, economical, and convenient treatment method for multiple palmoplantar warts, exhibiting few side effects and showing promise.Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Verrugas
/
Ácido Salicílico
Límite:
Humans
Idioma:
En
Revista:
Skin Res Technol
Asunto de la revista:
DERMATOLOGIA
Año:
2024
Tipo del documento:
Article
País de afiliación:
China